OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $602,000 in ProQR Therapeutics (NASDAQ:PRQR)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 227,020 shares of the biopharmaceutical company’s stock, valued at approximately $602,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.28% of ProQR Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the stock. Affinity Asset Advisors LLC purchased a new position in ProQR Therapeutics during the fourth quarter valued at approximately $7,486,000. M&T Bank Corp bought a new position in ProQR Therapeutics in the 4th quarter valued at $330,000. ArrowMark Colorado Holdings LLC purchased a new position in shares of ProQR Therapeutics during the 4th quarter valued at $3,131,000. XTX Topco Ltd bought a new position in shares of ProQR Therapeutics in the fourth quarter worth $163,000. Finally, Altium Capital Management LLC purchased a new stake in shares of ProQR Therapeutics in the fourth quarter worth $1,524,000. Hedge funds and other institutional investors own 32.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PRQR shares. HC Wainwright upped their target price on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, March 14th. Cantor Fitzgerald assumed coverage on shares of ProQR Therapeutics in a research report on Tuesday, April 29th. They issued an “overweight” rating and a $8.00 price objective on the stock. Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a research report on Monday, March 10th. Oppenheimer cut their price target on shares of ProQR Therapeutics from $15.00 to $9.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Evercore ISI started coverage on shares of ProQR Therapeutics in a research report on Tuesday, April 29th. They set an “outperform” rating and a $5.00 price objective on the stock. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

ProQR Therapeutics Price Performance

Shares of NASDAQ PRQR opened at $1.53 on Wednesday. The stock has a market capitalization of $160.98 million, a P/E ratio of -4.78 and a beta of 0.35. ProQR Therapeutics has a one year low of $1.07 and a one year high of $4.62. The firm’s 50 day simple moving average is $1.48 and its two-hundred day simple moving average is $2.37.

ProQR Therapeutics (NASDAQ:PRQR) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The business had revenue of $4.89 million for the quarter, compared to the consensus estimate of $4.90 million. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. As a group, equities analysts expect that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).